In early 2024, the bird influenza that had been spreading across the globe for nearly three decades did something wholly ...

In the past two years, a disease-causing strain of avian flu, known as H5N1 or bird flu, has impacted 1,046 flocks across the ...

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses ...

As scientists, we often think we understand a virus—its structure, its tricks, the way it moves through the body. But every ...

The current outbreak of the Asian Influenza virus in poultry may mutate to humans ... we add R9.5bn to the cost structure of the industry that's material, and that is then given through to the ...

Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations ...

Stock analysts at Zacks Small Cap issued their Q1 2025 earnings per share (EPS) estimates for Cocrystal Pharma in a research ...

Equities research analysts at Zacks Small Cap issued their Q3 2025 earnings per share (EPS) estimates for Cocrystal Pharma in a research report issued to clients and investors on Tuesday, April 1st.